Global Medical Devices Overview for 2025

This blog was originally posted on 20th January, 2026. Further regulatory developments may have occurred after publication. To keep up-to-date with the latest compliance news, sign up to our newsletter.

AUTHORED BY FERNANDA PARO, SENIOR REGULATORY COMPLIANCE SPECIALIST, COMPLIANCE & RISKS

---

The global medical devices sector continues to play a critical role in modern healthcare systems, enabling prevention, diagnosis, treatment, and long-term management of diseases across diverse clinical settings. As healthcare demand rises due to aging populations, the increasing prevalence of chronic diseases, and expanding access to care in emerging markets, medical devices remain central to improving patient outcomes, operational efficiency, and healthcare sustainability.

The medical devices industry is characterized by rapid technological innovation and evolving regulatory frameworks. Advances in digital health, artificial intelligence (AI), minimally invasive technologies, and connected medical devices are reshaping traditional care models while introducing new regulatory, ethical, and cybersecurity considerations. At the same time, global supply chain resilience, post-pandemic preparedness, and cost containment remain top priorities for healthcare stakeholders.

This blog provides an overview of the global medical devices landscape in 2025, with a focus on the second half of the year. It summarizes the regulatory developments, and regional dynamics to support strategic decision-making for manufacturers, policymakers, healthcare providers, and investors. The analysis draws upon authoritative industry guidelines (which are of high importance in this sector) and regulatory publications to present a balanced and forward-looking perspective on the sector.

Want to take a deep dive into Medical Devices in the Age of AI and Cybersecurity? Check out our webinar-on-demand!

Key Publications

Between the second half of 2025 and early 2026, several influential global guidelines have been published or progressed across critical sectors, underscoring a renewed focus on coordinated international action. 

Key publications include the following:

USA (FDA)

1. Clinical Decision Support Software: It excludes certain medical software functions, including certain decision support software, from the definition of device under section 201(h) of the FD&C Act
2. Investigator Responsibilities – Safety Reporting for Investigational Drugs and Devices
3. Use of real-world evidence to support Regulatory Decision-Making for Medical Devices
4. Draft Guidance Study of sex differences in the clinical evaluation of Medical products
5. Promotional Labeling and Advertising Considerations for Prescription Biological Reference Products, Biosimilar Products, and Interchangeable Biosimilar Products: Questions and Answers

EU

1. MDCG 2025-7 Rev. 1
2. MDCG 2025-8
3. MDCG Guidance Draft 2025-X
4. Update the Borderline & Classification Manual

Australia

1. Conformity Assessment Procedures for Medical Devices Proposed Amendments

Brazil

1. Manual for the Registration of Medical Devices (Health-Use Materials) 
2. Manual for the Regulatory Approval of Medical Equipment and Software as a Medical Device at Anvisa

Egypt

1. Regulatory Guidance for adding/transferring manufacturing site for registered local human & veterinary medical products

UK

1. Medical devices: get regulatory advice from the MHRA

Malaysia

1. Guidance on Definition of medical device
2. Change management for registered medical devices
3. Harmonized classification of medical devices in ASEAN

Canada

1. IMDRF table of contents for medical devices applications guidance
2. Guidance on managing applications for medical device licences

Switzerland

1. User Guide – playground explains how to register actors, upload UDIs, and test device registration processes

IMDRF

1. Characterization Considerations for Medical Device Software and Software-Specific Risk
2. Good machine learning practice for medical device development: Guiding principles
3. Terminologies for Categorized Adverse Event Reporting (AER): terms, terminology and codes
4. Medical Devices: Post-Market Surveillance: National Competent Authority Report Exchange Criteria and Report Form
5. IMDRF Document Implementation Report

WHO

1. Global strategy on digital health 2020-2027
2. Development of medical devices policies

What’s Happening in Europe?

In terms of laws and proposals, 2025 was also busy for the medical device regulatory framework, with both implementation milestones and forward-looking reforms. In the EU, the European Health Data Space Regulation entered into force, introducing new obligations on health data use and interoperability that are particularly relevant for connected and software-based medical devices. Also, Commission Decision (EU) 2025/2371 confirmed the functionality of key EUDAMED modules for medical devices and in vitro diagnostics, enabling the transition toward mandatory system use under the MDR and IVDR. 

In parallel, the EU Digital Omnibus package introduced horizontal digital initiatives that may indirectly impact medical device manufacturers, particularly in areas such as data governance and AI compliance. 

At national level within the EU, countries such as Portugal adopted implementing legislation (Law No. 71/2025) to align domestic rules with MDR and IVDR requirements. In Great Britain, amendments to the Medical Devices Regulations and new post-market surveillance requirements took effect, marking a significant step in the UK’s post-Brexit regulatory framework. 

At the same time, the proposed revisions of the MDR and IVDR, along with the draft revision of MDR Annex VII, aim to streamline conformity assessment processes, enhance notified body oversight, and reduce administrative burden while maintaining high levels of patient safety.

Smarter Sustainability Compliance

Cut through the noise of ESG regulations with AI-powered insights you can actually use.

Try Free

What’s Happening in Asia?

In Asia, China’s National Medical Products Administration issued a new Medical Devices Good Manufacturing Practice (GMP) framework at the end of 2025. Although its effective date is in 2026, its publication represents a significant legally binding overhaul of device quality and lifecycle requirements in the world’s largest medical device manufacturing market. 

Also, Japan’s Ministry of Health, Labour and Welfare published Cabinet Order No. 362 of 2025, revising aspects of the enforcement of the Pharmaceuticals and Medical Devices Act to include provisions on clinical study definitions and recognition of foreign regulators (such as the FDA) as equivalent for priority review. These changes were announced in late 2025 with effect starting May 1 2026.

For more information on medical device developments in Asia, grab a copy of our whitepaper ‘Cybersecurity and AI Requirements in Medical Devices in Asia’.

Global Developments

As the global medical devices landscape moves through the second half of 2025 and into early 2026, manufacturers and stakeholders face an increasingly complex yet opportunity-rich environment. Rapid technological advances, particularly in digital health, software, and AI-driven solutions, continue to reshape care delivery while prompting regulators worldwide to refine and align their oversight frameworks. The breadth of new guidelines, legislative developments, and regulatory initiatives across major markets underscores a clear trend toward stronger international coordination, enhanced post-market vigilance, and greater emphasis on data integrity, patient safety, and innovation governance. 

In this context, proactive regulatory intelligence, early compliance planning, and continuous engagement with evolving requirements will be essential for organizations seeking to maintain market access, manage risk, and sustainably innovate in a highly dynamic global healthcare ecosystem.

Stay Ahead Of Regulatory Changes in the Medical Device Regulatory Landscape

Want to stay ahead of regulatory developments in the Medical Device Regulatory Landscape?

Accelerate your ability to achieve, maintain & expand market access for all products in global markets with C2P, your key to unlocking market access, trusted by more than 300 of the world’s leading brands. C2P is an enterprise SaaS platform providing everything you need in one place to achieve your business objectives by proving compliance in over 195 countries.

C2P is purpose-built to be tailored to your specific needs with comprehensive capabilities that enable enterprise-wide management of regulations, standards, requirements and evidence.
Add-on packages help accelerate market access through use-case-specific solutions, global regulatory content, a global team of subject matter experts and professional services.

• Accelerate time-to-market for products
• Reduce non-compliance risks that impact your ability to meet business goals and cause reputational damage
• Enable business continuity by digitizing your compliance process and building corporate memory
• Improve efficiency and enable your team to focus on business critical initiatives rather than manual tasks
• Save time with access to Compliance & Risks’ extensive Knowledge Partner network

Simplify Corporate Sustainability Compliance

Six months of research, done in 60 seconds. Cut through ESG chaos and act with clarity. Try C&R Sustainability Free.

START TRIAL